You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Details for Patent: 9,579,359

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,579,359 protect, and when does it expire?

Patent 9,579,359 protects FIRMAGON and is included in one NDA.

This patent has one hundred and three patent family members in twenty-four countries.

Summary for Patent: 9,579,359

Title:	Method of treating prostate cancer with GnRH antagonist
Abstract:	The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Inventor(s):	Olesen; Tine Kold (New York, NY), Persson; Bo-Eric (Rolle, DK), Cantor; Per (Charlottenlund, DK), van der Meulen; Egbert A (Dalby, SE), Jensen; Jens-Kristian Slott (Bagsvaerd, DK)
Assignee:	FERRING B.V. (Hoofdorp, NL)
Application Number:	14/139,922
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,579,359
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,579,359

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT	⤷ Sign Up
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-002	Dec 24, 2008		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,579,359

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	08250703	Feb 29, 2008

International Family Members for US Patent 9,579,359

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009213748	⤷ Sign Up
Australia	2009213751	⤷ Sign Up
Brazil	PI0908127	⤷ Sign Up
Brazil	PI0908129	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.